Integra LifeSciences Holdings Co. (NASDAQ:IART) Position Lowered by Bank of New York Mellon Corp

Bank of New York Mellon Corp reduced its position in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 3.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 467,962 shares of the life sciences company’s stock after selling 15,830 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.61% of Integra LifeSciences worth $10,613,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of IART. Sachem Head Capital Management LP bought a new stake in shares of Integra LifeSciences in the 3rd quarter valued at approximately $44,153,000. Charles Schwab Investment Management Inc. boosted its holdings in Integra LifeSciences by 15.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 944,282 shares of the life sciences company’s stock worth $17,158,000 after purchasing an additional 125,620 shares during the period. Glenmede Trust Co. NA increased its stake in Integra LifeSciences by 125.9% during the third quarter. Glenmede Trust Co. NA now owns 727,781 shares of the life sciences company’s stock valued at $13,224,000 after purchasing an additional 405,624 shares during the last quarter. Systematic Financial Management LP raised its holdings in shares of Integra LifeSciences by 53.9% during the third quarter. Systematic Financial Management LP now owns 611,746 shares of the life sciences company’s stock worth $11,115,000 after purchasing an additional 214,272 shares during the period. Finally, Principal Financial Group Inc. lifted its position in shares of Integra LifeSciences by 5.5% in the 4th quarter. Principal Financial Group Inc. now owns 423,432 shares of the life sciences company’s stock worth $9,603,000 after buying an additional 22,000 shares during the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

Analysts Set New Price Targets

Separately, Morgan Stanley started coverage on shares of Integra LifeSciences in a research report on Monday, December 2nd. They set an “underweight” rating and a $20.00 price objective for the company. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, Integra LifeSciences currently has a consensus rating of “Hold” and a consensus target price of $23.00.

Integra LifeSciences Stock Up 0.1 %

IART stock opened at $22.27 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The firm’s 50-day simple moving average is $23.81 and its 200 day simple moving average is $21.94. The stock has a market cap of $1.72 billion, a PE ratio of -247.42, a price-to-earnings-growth ratio of 0.73 and a beta of 1.23. Integra LifeSciences Holdings Co. has a fifty-two week low of $16.81 and a fifty-two week high of $35.91.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.85 by $0.12. The company had revenue of $442.65 million for the quarter, compared to analyst estimates of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. Integra LifeSciences’s revenue was up 11.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.89 earnings per share. As a group, sell-side analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.